ICU Medical, Inc. (NASDAQ:ICUI) Receives Consensus Recommendation of “Buy” from Analysts

Shares of ICU Medical, Inc. (NASDAQ:ICUI) have been assigned an average rating of “Buy” from the six ratings firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, three have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $168.00.

A number of analysts have recently weighed in on the company. KeyCorp cut their price objective on ICU Medical from $180.00 to $164.00 and set an “overweight” rating on the stock in a research report on Monday, April 27th. Piper Sandler cut their price objective on ICU Medical from $178.00 to $163.00 and set an “overweight” rating on the stock in a research report on Friday, April 17th. Needham & Company LLC raised ICU Medical from a “hold” rating to a “buy” rating and set a $165.00 price objective on the stock in a research report on Wednesday, May 27th. Weiss Ratings raised ICU Medical from a “sell (d)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Finally, Jefferies Financial Group raised ICU Medical to a “strong-buy” rating in a research report on Thursday, May 7th.

ICU Medical Stock Down 2.8%

NASDAQ:ICUI opened at $131.64 on Tuesday. The company has a quick ratio of 1.17, a current ratio of 2.34 and a debt-to-equity ratio of 0.60. The stock’s fifty day moving average is $126.34 and its two-hundred day moving average is $138.75. ICU Medical has a 52 week low of $107.00 and a 52 week high of $160.29. The stock has a market capitalization of $3.29 billion, a price-to-earnings ratio of 71.16, a price-to-earnings-growth ratio of 1.89 and a beta of 0.77.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.97 earnings per share for the quarter, topping analysts’ consensus estimates of $1.78 by $0.19. ICU Medical had a return on equity of 7.50% and a net margin of 2.15%.The business had revenue of $525.77 million for the quarter, compared to analyst estimates of $520.65 million. During the same quarter in the prior year, the company earned $1.72 earnings per share. The company’s revenue was down 12.3% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. Research analysts anticipate that ICU Medical will post 6.5 EPS for the current year.

Insiders Place Their Bets

In other news, Director David C. Greenberg sold 2,424 shares of the company’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $122.91, for a total transaction of $297,933.84. Following the sale, the director owned 7,960 shares of the company’s stock, valued at approximately $978,363.60. This represents a 23.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Virginia Ruth Sanzone sold 2,447 shares of the stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $124.08, for a total value of $303,623.76. Following the completion of the transaction, the vice president directly owned 19,460 shares in the company, valued at $2,414,596.80. This trade represents a 11.17% decrease in their position. The SEC filing for this sale provides additional information. 2.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On ICU Medical

Several large investors have recently bought and sold shares of ICUI. Hilton Head Capital Partners LLC purchased a new position in ICU Medical in the fourth quarter valued at $32,000. Covestor Ltd increased its holdings in ICU Medical by 22.1% in the fourth quarter. Covestor Ltd now owns 696 shares of the medical instruments supplier’s stock valued at $99,000 after buying an additional 126 shares during the last quarter. Strs Ohio increased its holdings in ICU Medical by 60.0% in the fourth quarter. Strs Ohio now owns 800 shares of the medical instruments supplier’s stock valued at $114,000 after buying an additional 300 shares during the last quarter. Rockefeller Capital Management L.P. increased its holdings in ICU Medical by 21.6% in the fourth quarter. Rockefeller Capital Management L.P. now owns 823 shares of the medical instruments supplier’s stock valued at $117,000 after buying an additional 146 shares during the last quarter. Finally, Kemnay Advisory Services Inc. purchased a new position in ICU Medical in the fourth quarter valued at $120,000. Hedge funds and other institutional investors own 96.10% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.